New Developments in Allergic Asthma Treatment

Allergic asthma is the most common form of asthma and can occur when a patient’s airways are extra sensitive to certain allergens. Symptoms include coughing/wheezing, shortness of breath, quick breathing or chest tightness. Allergic asthma is most commonly treated with  antihistamines, inhaled steroids, and bronchodilators. Longer-lasting treatments are also available.

This education center aims to arm physicians with the latest, most important, and most practice-changing research in prevention, treatment, and management of allergic asthma.

 
Dupilumab Shows Safety, Efficacy for 3 years in Moderate-to-Severe Asthma

Dupilumab Shows Safety, Efficacy for 3 years in Moderate-to-Severe Asthma

Results from the phase 3 open-label extension study LIBERTY ASTHMA TRAVERSE show dupilumab remains safe and effective for up to 3 years in patients with moderate-to-severe asthma...
IRIDIUM Study: Inhaled Combination Improves Lung Function for Uncontrolled Asthma

IRIDIUM Study: Inhaled Combination Improves Lung Function for Uncontrolled Asthma

A once-daily, single-inhaler combination of mometasone furoate, indacaterol acetate, and glycopyrronium bromide improved lung function in patients with inadequately controlled asthma...
Uptick in Night-Time Cough Measured with Smartphone App May Portend Worsening Asthma

Uptick in Night-Time Cough Measured with Smartphone App May Portend Worsening Asthma

An increase in night-time coughing, measured using a smartphone app, may be a sign of worsening asthma...
Global Quality Standard Needed For Identification of Severe Asthma Patients

Global Quality Standard Needed For Identification of Severe Asthma Patients

According to a recent commentary in Advances in Therapy, clinicians call for a global quality standard for the identification and management of severe asthma....
Mepolizumab Best as Maintenance Therapy for Patients with Severe Eosinophilic Asthma

Mepolizumab Best as Maintenance Therapy for Patients with Severe Eosinophilic Asthma

Evidence from a phase 3 trial indicates that patients with severe eosinophilic asthma who stopped mepolizumab after 3 years or more of use had worsened outcomes...

Loading...

© 2020 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use
Do Not Sell My Personal Information